Sangamo Therapeutics, Inc. (FRA:GBY)

Market Cap	90.18M -30.3%
Revenue (ttm)	33.69M -31.6%
Net Income	-104.70M
EPS	-0.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	52
Open	0.2100
Previous Close	0.1962
Day's Range	0.2072 - 0.2100
52-Week Range	0.1597 - 0.6831
Beta	n/a
RSI	47.17
Earnings Date	Mar 30, 2026

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 142
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GBY

Financial Performance

In 2025, Sangamo Therapeutics's revenue was $39.55 million, a decrease of -31.57% compared to the previous year's $57.80 million. Losses were -$122.93 million, 25.5% more than in 2024.

Financial numbers in USD